Logo image of FBIO

FORTRESS BIOTECH INC (FBIO) Stock Fundamental Analysis

USA - NASDAQ:FBIO - US34960Q3074 - Common Stock

2.56 USD
-1.13 (-30.62%)
Last: 10/1/2025, 2:00:25 PM
Fundamental Rating

2

FBIO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. FBIO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, FBIO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FBIO has reported negative net income.
FBIO had a negative operating cash flow in the past year.
FBIO had negative earnings in each of the past 5 years.
In the past 5 years FBIO always reported negative operating cash flow.
FBIO Yearly Net Income VS EBIT VS OCF VS FCFFBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -15.04%, FBIO belongs to the top of the industry, outperforming 81.90% of the companies in the same industry.
The Return On Equity of FBIO (-54.76%) is better than 64.18% of its industry peers.
Industry RankSector Rank
ROA -15.04%
ROE -54.76%
ROIC N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
FBIO Yearly ROA, ROE, ROICFBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

1.3 Margins

With an excellent Gross Margin value of 70.91%, FBIO belongs to the best of the industry, outperforming 81.90% of the companies in the same industry.
In the last couple of years the Gross Margin of FBIO has declined.
FBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
FBIO Yearly Profit, Operating, Gross MarginsFBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

1

2. Health

2.1 Basic Checks

FBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FBIO has been increased compared to 1 year ago.
FBIO has more shares outstanding than it did 5 years ago.
FBIO has a worse debt/assets ratio than last year.
FBIO Yearly Shares OutstandingFBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FBIO Yearly Total Debt VS Total AssetsFBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

FBIO has an Altman-Z score of -7.34. This is a bad value and indicates that FBIO is not financially healthy and even has some risk of bankruptcy.
FBIO has a Altman-Z score of -7.34. This is in the lower half of the industry: FBIO underperforms 66.98% of its industry peers.
FBIO has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
FBIO's Debt to Equity ratio of 1.14 is on the low side compared to the rest of the industry. FBIO is outperformed by 77.80% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF N/A
Altman-Z -7.34
ROIC/WACCN/A
WACC11.41%
FBIO Yearly LT Debt VS Equity VS FCFFBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

2.3 Liquidity

A Current Ratio of 1.92 indicates that FBIO should not have too much problems paying its short term obligations.
With a Current ratio value of 1.92, FBIO is not doing good in the industry: 76.68% of the companies in the same industry are doing better.
A Quick Ratio of 1.70 indicates that FBIO should not have too much problems paying its short term obligations.
The Quick ratio of FBIO (1.70) is worse than 78.54% of its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.7
FBIO Yearly Current Assets VS Current LiabilitesFBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.44% over the past year.
The Revenue for FBIO has decreased by -28.23% in the past year. This is quite bad
The Revenue has been growing by 9.50% on average over the past years. This is quite good.
EPS 1Y (TTM)37.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.51%
Revenue 1Y (TTM)-28.23%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%10.18%

3.2 Future

Based on estimates for the next years, FBIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.48% on average per year.
Based on estimates for the next years, FBIO will show a very strong growth in Revenue. The Revenue will grow by 64.44% on average per year.
EPS Next Y75.36%
EPS Next 2Y25.07%
EPS Next 3Y11.48%
EPS Next 5YN/A
Revenue Next Year43.96%
Revenue Next 2Y43.21%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FBIO Yearly Revenue VS EstimatesFBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIO Yearly EPS VS EstimatesFBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBIO Price Earnings VS Forward Price EarningsFBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIO Per share dataFBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.07%
EPS Next 3Y11.48%

More info and screens

0

5. Dividend

5.1 Amount

FBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTRESS BIOTECH INC

NASDAQ:FBIO (10/1/2025, 2:00:25 PM)

2.56

-1.13 (-30.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners16.67%
Inst Owner Change4.33%
Ins Owners14.9%
Ins Owner Change0.06%
Market Cap76.16M
Analysts82.22
Price Target11.22 (338.28%)
Short Float %16.12%
Short Ratio4.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-2.8%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.62%
Min EPS beat(2)-36.17%
Max EPS beat(2)4.93%
EPS beat(4)2
Avg EPS beat(4)-13.52%
Min EPS beat(4)-36.17%
Max EPS beat(4)4.93%
EPS beat(8)6
Avg EPS beat(8)17.06%
EPS beat(12)7
Avg EPS beat(12)9.15%
EPS beat(16)8
Avg EPS beat(16)-15.31%
Revenue beat(2)2
Avg Revenue beat(2)10.78%
Min Revenue beat(2)10.71%
Max Revenue beat(2)10.85%
Revenue beat(4)2
Avg Revenue beat(4)-10.74%
Min Revenue beat(4)-55.48%
Max Revenue beat(4)10.85%
Revenue beat(8)4
Avg Revenue beat(8)13.91%
Revenue beat(12)5
Avg Revenue beat(12)3.45%
Revenue beat(16)7
Avg Revenue beat(16)-0.99%
PT rev (1m)-28.26%
PT rev (3m)-28.26%
EPS NQ rev (1m)-5%
EPS NQ rev (3m)-16.67%
EPS NY rev (1m)43.57%
EPS NY rev (3m)43.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.01%
Revenue NY rev (1m)-1.15%
Revenue NY rev (3m)-1.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.28
P/FCF N/A
P/OCF N/A
P/B 1.73
P/tB 5.37
EV/EBITDA N/A
EPS(TTM)-2.49
EYN/A
EPS(NY)-1.42
Fwd EYN/A
FCF(TTM)-3.2
FCFYN/A
OCF(TTM)-2.69
OCFYN/A
SpS1.99
BVpS1.48
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.04%
ROE -54.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.91%
FCFM N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.7
Altman-Z -7.34
F-Score4
WACC11.41%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.51%
EPS Next Y75.36%
EPS Next 2Y25.07%
EPS Next 3Y11.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-28.23%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%10.18%
Revenue Next Year43.96%
Revenue Next 2Y43.21%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%
EBIT growth 1Y-13.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.89%
EBIT Next 3Y5.48%
EBIT Next 5YN/A
FCF growth 1Y43.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.22%
OCF growth 3YN/A
OCF growth 5YN/A